Roche unveils CoaguChek INRange system with Bluetooth connectivity

30 May 2016 (Last Updated May 30th, 2016 18:30)

Roche has unveiled its CoaguChek INRange system to assist healthcare providers (HCPs) and patients to control their coagulation status and monitor vitamin k antagonist (VKA) therapy.

Roche has unveiled its CoaguChek INRange system to assist healthcare providers (HCPs) and patients to control their coagulation status and monitor vitamin k antagonist (VKA) therapy.

The new system is a hand-held home health device featuring an intuitive user-interface allowing flexible connectivity of patients with healthcare providers through Bluetooth technology involving an easy fingerstick and 60-second test.

It allows the patient, who is on an oral anticoagulant therapy, to monitor their coagulation status and relay the information to clinicians resulting in optimal therapy management.

"This innovative technology continues the CoaguChek legacy of setting the standard in coagulation monitoring by providing high-quality, convenient care, while optimising outcomes for patients."

The device requires minimal training and issues medication and testing reminders, flagging of results in relation to the target range and has the option to insert comments to the result.

It facilitates a better understanding of the patient's prothrombin time international normalised ratio (PT / INR) results through frequent self-testing which reduces the number of the patient's hospital visits and allow them to independently track their status in the therapy while continuing their daily activities.

Roche Diagnostics COO Roland Diggelmann said: "As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between HCPs and patients becomes even more important.

"This innovative technology continues the CoaguChek legacy of setting the standard in coagulation monitoring by providing high-quality, convenient care, while optimising outcomes for patients.

"This is another proof point towards our aim to position patient self-testing as the standard of care to monitor VKA therapy."